Metanova Labs: Bittensor revolutionizes drug discovery with decentralized virtual screening, combinatorial reactions expand possibilities to 65 billion, and dual incentives drive innovation | TWIST

Metanova Labs is revolutionizing drug discovery by using Bittensor's decentralized AI network to screen billions of molecules efficiently. The platform utilizes combinatorial reactions to expand screening possibilities to 65 billion compounds and implements dual incentive mechanisms to drive innovation in pharmaceutical research.

• →Metanova Labs leverages Bittensor's decentralized AI infrastructure for large-scale molecular screening in drug discovery
• →The platform can screen up to 65 billion molecular combinations through advanced combinatorial reaction techniques
• →Decentralized virtual screening offers more efficient drug discovery processes compared to traditional methods
• →Dual incentive mechanisms are designed to encourage innovation and participation in the network
• →The project represents a significant application of AI-crypto integration in the pharmaceutical industry